| 000 | 01698 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513174444.0 | ||
| 264 | 0 | _c19990415 | |
| 008 | 199904s 0 0 eng d | ||
| 022 | _a0002-9149 | ||
| 024 | 7 |
_a10.1016/s0002-9149(98)01066-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDelea, T E | |
| 245 | 0 | 0 |
_aCost effectiveness of carvedilol for heart failure. _h[electronic resource] |
| 260 |
_bThe American journal of cardiology _cMar 1999 |
||
| 300 |
_a890-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdrenergic beta-Antagonists _xeconomics |
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aCarbazoles _xeconomics |
| 650 | 0 | 4 |
_aCardiotonic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aCarvedilol |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aDigoxin _xadministration & dosage |
| 650 | 0 | 4 |
_aDiuretics _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 |
_aHeart Failure _xdrug therapy |
| 650 | 0 | 4 | _aHospitalization |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLife Expectancy |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 |
_aPropanolamines _xeconomics |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aVasodilator Agents _xeconomics |
| 700 | 1 | _aVera-Llonch, M | |
| 700 | 1 | _aRichner, R E | |
| 700 | 1 | _aFowler, M B | |
| 700 | 1 | _aOster, G | |
| 773 | 0 |
_tThe American journal of cardiology _gvol. 83 _gno. 6 _gp. 890-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0002-9149(98)01066-2 _zAvailable from publisher's website |
| 999 |
_c10149848 _d10149848 |
||